Clinical Trials Update: Sept. 10, 2007
Depression (Treatment-Resistant) Emphysema Prostate Cancer
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This 10-week study will evaluate rEEG technology in determining the most effective medication for people with treatment-resistant depression. Participants must be 18 or older, diagnosed with major depressive disorder, and must have failed three or more antidepressant treatments. Additional criteria apply.
The research site is in Chicago, Ill.
This study will evaluate an investigational device designed to improve the health and quality of life of people with emphysema. Participants must be ages 40 to 74; have mostly upper lobe, severe emphysema; be able to participate in standard exercise testing; and be willing to abstain from cigarette smoking for four months during the trial. Additional criteria apply.
The research site is in Las Vegas, Nev.
This study will compare investigational GVAX immunotherapy in combination with docetaxel and prednisone in taxane-naive patients with metastatic hormone-refractory prostate cancer with pain. Participants must have confirmed diagnosis of -- or clinical history consistent with -- adenocarcinoma of the prostate. Additional criteria apply.
The research site is in Decatur, Ga.
Copyright 2007 Thomson CenterWatch. All rights reserved.